LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Anticoagulation therapy using unfractionated heparin at a therapeutic dose for coronavirus disease 2019 patients with severe pneumonia: a retrospective historical control study.

Takayama, Wataru / Endo, Akira / Otomo, Yasuhiro

Acute medicine & surgery

2021  Volume 8, Issue 1, Page(s) e679

Abstract: ... with unfractionated heparin to treat severe COVID-19.: Methods: We conducted a retrospective historical control study ... Aim: Patients with severe coronavirus disease 2019 (COVID-19) pneumonia often have complications ... Conclusions: Therapeutic-dose anticoagulation may be beneficial for patients with severe COVID-19 pneumonia ...

Abstract Aim: Patients with severe coronavirus disease 2019 (COVID-19) pneumonia often have complications of coagulopathy and thrombotic phenomena, which lead to high mortality. Whether administering systematic anticoagulant therapy is beneficial remains unclear. We report our experience using systemic anticoagulation with unfractionated heparin to treat severe COVID-19.
Methods: We conducted a retrospective historical control study of severe COVID-19 patients requiring mechanical ventilation who received prophylactic-dose anticoagulation (April 1-May 25) or therapeutic-dose anticoagulation (May 26-August 31) in the intensive care unit (ICU) of a tertiary emergency critical care medical center in Japan. The primary endpoints were in-hospital mortality and anticoagulation therapy-related adverse events. The secondary endpoints included thromboembolic events, administration of venovenous extracorporeal membrane oxygenation (ECMO), ventilator-free days (VFDs), ICU-free days, and the development of multiple organ dysfunction syndrome.
Results: A total of 29 and 33 patients were in the prophylactic-dose and therapeutic-dose groups, respectively. Background characteristics between the groups were not significantly different, although the therapeutic-dose group had a significantly lower in-hospital mortality rate [5 (17.2%) patients versus 0 (0.0%) patients;
Conclusions: Therapeutic-dose anticoagulation may be beneficial for patients with severe COVID-19 pneumonia requiring mechanical ventilation.
Language English
Publishing date 2021-06-30
Publishing country United States
Document type Journal Article
ZDB-ID 2751184-4
ISSN 2052-8817 ; 2052-8817
ISSN (online) 2052-8817
ISSN 2052-8817
DOI 10.1002/ams2.679
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top